Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmetramadol (Primary) ; Tramadol
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Syntrix Biosystems
  • Most Recent Events

    • 31 Oct 2019 According to an Syntrix Pharmaceuticals media release, positive desmetramadol trial was featured on the October 2019 cover of The Journal of Pain, the official journal of the American Pain Society.
    • 04 Jun 2019 Results from this and another phase I trial (profile 289610) presented in a Syntrix Biosystems media release.
    • 18 Apr 2019 Results evaluating steady-state pharmacokinetics, efficacy and safety of desmetramadol versus placebo and versus tramadol published in the Journal of Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top